Morepen Laboratories adds 3 more drugs to API portfolio

Morepen Laboratories Limited on Monday informed the exchanges that it has developed and added three drugs to its portfolio of Active Pharmaceutical Ingredients for sale in domestic and global markets.

The three bulk drugs are Rivaroxaban (Cardiac Segment), Vidagliptin (Diabetes Segment) and UDCA (for Lever ailments). Rivaroxaban is the 10th largest selling drug worldwide. Vidagliptin has 25 per cent share of Indian Gliptins market which valued at Rs. 3,500 crore. UCDA is used for treatment of primary biliary cirrhosis, a lever disease which occurs due to improper functioning of lever.

Morepen Laboratories Limited (MLI) is an Indian pharmaceutical company with its headquarters in New Delhi, India. MLI is world’s largest generic player of Loratadine with more than 80 per cent US generic market shares. The company manufactures and sells Active Pharmaceutical Ingredients (API), Home Diagnostics and Finished Formulation to more than 50 countries. Morepen’s key product areas includes, Active Pharmaceutical Ingredients, Branded Prescription Drugs, Diagnostics and Over the counter products.

On Monday, the stock of Morepen Laboratories opened at Rs. 15.70 per share and made an intraday high and low of Rs. 15.80 and Rs. 12.70, respectively on the BSE. At 15.00 hours, the stock was trading at Rs. 15.30, down by 2.55 per cent.